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Background
Major challenges to advancing the new wave of cancer
immunotherapies are to select patients who will respond
to single immunotherapies, identify those who need
more tailored combination regimens, and then, deter-
mine early during treatment whether the therapy is work-
ing. “ImmunoPET” imaging of tumor infiltrating T cells
with radiolabeled antibody fragments can provide a spe-
cific and sensitive modality to achieve this goal. For this
purpose we have developed 89Zr-Df-IAB22M2C, an anti-
CD8 minibody (Mb) conjugated with desferrioxamine
(Df) and radiolabeled with 89Zr for imaging human CD8
+T cells in man.
Methods
Df-isothiocyanate was conjugated to IAB22M2C on lysine
residues and the biologic activity assessed using a panel of
functional and biochemical assays. After radiolabeling with
89Zr, pharmacokinetic, biodistribution and PET imaging
studies were performed in NOD scid gamma (NOD.Cg-
Prkdcscid Il2rgtm1Wjl/SzJ; NSG) mice engrafted with
human peripheral blood mononuclear cells (PBMCs) or
CD34+ stem cells.
Results
Conjugation of IAB22M2C with Df chelators did
not impact structural integrity or binding to CD8 (EC50
1.2 nM). A panel of in vitro functional assays using
donor PBMCs demonstrated that Df-IAB22M2C did not
activate or stimulate T cells to proliferate. Importantly,
Df-IAB22M2C did not deplete or activate human T cells
in NSG mice engrafted with human CD34+ stem cells.
NSG mice engrafted with human PBMCs are reproducible
models of xenogeneic Graft Versus Host Disease (GVHD).
89Zr-Df-IAB22M2C, radiolabeled to a specific activity of
~30-40 µCi/µg, was able to detect CD8+T in the spleens of
mice one week post PBMC engraftment. As GVHD pro-
gressed 4-5 weeks later, expansion and trafficking of the
engrafted T cells to extra-lymphoid tissues including lungs
could be followed. Terminal biodistribution showed a
2-3 fold increase in radioactivity uptake in lungs (from 4
to 9.2 % ID/gm) at 1 and 4 weeks respectively; a result
that was confirmed by IHC analysis. 89Zr-Df-IAB22M2C
clearance followed a biphasic distribution with a terminal
half-life of approximately 2.7 hrs indicating that same day
imaging is likely in humans. These results are being
extended to include human tumor models implanted in
humanized mice.
Conclusion
89Zr-Df-IAB22M2C radiolabeled to high specific activity
can be used to track T cell trafficking in vivo and will
provide a sensitive means for monitoring CD8+T cell
distribution in patients treated with different immu-
notherapies. The safety profile and biochemical proper-
ties of 89Zr-Df-IAB22M2C in vitro and in vivo support
the commencement of human clinical trials with this
probe early next year.
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